132 related articles for article (PubMed ID: 38262243)
1. 5-Hydroxymethylcytosine signals in serum are a predictor of chemoresistance in high-grade serous ovarian cancer.
Weigert M; Cui XL; West-Szymanski D; Yu X; Bilecz AJ; Zhang Z; Dhir R; Kehoe M; Zhang W; He C; Lengyel E
Gynecol Oncol; 2024 Mar; 182():82-90. PubMed ID: 38262243
[TBL] [Abstract][Full Text] [Related]
2. Alterations of 5-hydroxymethylcytosines in circulating cell-free DNA reflect retinopathy in type 2 diabetes.
Han L; Chen C; Lu X; Song Y; Zhang Z; Zeng C; Chiu R; Li L; Xu M; He C; Zhang W; Duan S
Genomics; 2021 Jan; 113(1 Pt 1):79-87. PubMed ID: 33221518
[TBL] [Abstract][Full Text] [Related]
3. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer.
Tucker DW; Getchell CR; McCarthy ET; Ohman AW; Sasamoto N; Xu S; Ko JY; Gupta M; Shafrir A; Medina JE; Lee JJ; MacDonald LA; Malik A; Hasselblatt KT; Li W; Zhang H; Kaplan SJ; Murphy GF; Hirsch MS; Liu JF; Matulonis UA; Terry KL; Lian CG; Dinulescu DM
Clin Cancer Res; 2018 Mar; 24(6):1389-1401. PubMed ID: 29263182
[No Abstract] [Full Text] [Related]
5. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
Cohen S; Mosig R; Moshier E; Pereira E; Rahaman J; Prasad-Hayes M; Halpert R; Billaud JN; Dottino P; Martignetti JA
Gynecol Oncol; 2014 Sep; 134(3):591-8. PubMed ID: 24995581
[TBL] [Abstract][Full Text] [Related]
6. Gene networks and expression quantitative trait loci associated with adjuvant chemotherapy response in high-grade serous ovarian cancer.
Choi J; Topouza DG; Tarnouskaya A; Nesdoly S; Koti M; Duan QL
BMC Cancer; 2020 May; 20(1):413. PubMed ID: 32404140
[TBL] [Abstract][Full Text] [Related]
7. Unveiling the epigenomic mechanisms of acquired platinum-resistance in high-grade serous ovarian cancer.
Silva R; Glennon K; Metoudi M; Moran B; Salta S; Slattery K; Treacy A; Martin T; Shaw J; Doran P; Lynch L; Jeronimo C; Perry AS; Brennan DJ
Int J Cancer; 2023 Jul; 153(1):120-132. PubMed ID: 36883413
[TBL] [Abstract][Full Text] [Related]
8. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
9. Prognostic implications of 5-hydroxymethylcytosines from circulating cell-free DNA in diffuse large B-cell lymphoma.
Chiu BC; Zhang Z; You Q; Zeng C; Stepniak E; Bracci PM; Yu K; Venkataraman G; Smith SM; He C; Zhang W
Blood Adv; 2019 Oct; 3(19):2790-2799. PubMed ID: 31570490
[TBL] [Abstract][Full Text] [Related]
10. Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma.
Reid BM; Vyas S; Chen Z; Chen A; Kanetsky PA; Permuth JB; Sellers TA; Saglam O
BMC Cancer; 2021 Jun; 21(1):714. PubMed ID: 34140011
[TBL] [Abstract][Full Text] [Related]
11. OvaPrint-A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer.
Buckley DN; Lewinger JP; Gooden G; Spillman M; Neuman M; Guo XM; Tew BY; Miller H; Khetan VU; Shulman LP; Roman L; Salhia B
Clin Cancer Res; 2023 Dec; 29(24):5196-5206. PubMed ID: 37812492
[TBL] [Abstract][Full Text] [Related]
12. Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer.
Tomar T; Alkema NG; Schreuder L; Meersma GJ; de Meyer T; van Criekinge W; Klip HG; Fiegl H; van Nieuwenhuysen E; Vergote I; Widschwendter M; Schuuring E; van der Zee AGJ; de Jong S; Wisman GBA
BMC Med; 2017 Jun; 15(1):116. PubMed ID: 28641578
[TBL] [Abstract][Full Text] [Related]
13. 5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic and predictive biomarkers for coronary artery disease.
Dong C; Chen J; Zheng J; Liang Y; Yu T; Liu Y; Gao F; Long J; Chen H; Zhu Q; He Z; Hu S; He C; Lin J; Tang Y; Zhu H
Clin Epigenetics; 2020 Jan; 12(1):17. PubMed ID: 31964422
[TBL] [Abstract][Full Text] [Related]
14. 5-Hydroxymethylcytosine signature in circulating cell-free DNA as a potential diagnostic factor for early-stage colorectal cancer and precancerous adenoma.
Xiao Z; Wu W; Wu C; Li M; Sun F; Zheng L; Liu G; Li X; Yun Z; Tang J; Yu Y; Luo S; Sun W; Feng X; Cheng Q; Tao X; Wu S; Tao J
Mol Oncol; 2021 Jan; 15(1):138-150. PubMed ID: 33107199
[TBL] [Abstract][Full Text] [Related]
15. 5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA as Diagnostic Biomarkers for Late-Onset Alzheimer's Disease.
Chen L; Shen Q; Xu S; Yu H; Pei S; Zhang Y; He X; Wang Q; Li D
J Alzheimers Dis; 2022; 85(2):573-585. PubMed ID: 34864677
[TBL] [Abstract][Full Text] [Related]
16. 5-Hydroxymethylcytosine profiling from genomic and cell-free DNA for colorectal cancers patients.
Gao P; Lin S; Cai M; Zhu Y; Song Y; Sui Y; Lin J; Liu J; Lu X; Zhong Y; Cui Y; Zhou P
J Cell Mol Med; 2019 May; 23(5):3530-3537. PubMed ID: 30912288
[TBL] [Abstract][Full Text] [Related]
17. Liquid biopsy by combining 5-hydroxymethylcytosine signatures of plasma cell-free DNA and protein biomarkers for diagnosis and prognosis of hepatocellular carcinoma.
Cai Z; Zhang J; He Y; Xia L; Dong X; Chen G; Zhou Y; Hu X; Zhong S; Wang Y; Chen H; Xie D; Liu X; Liu J
ESMO Open; 2021 Feb; 6(1):100021. PubMed ID: 33508734
[TBL] [Abstract][Full Text] [Related]
18. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
[TBL] [Abstract][Full Text] [Related]
19. 5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers.
Li W; Zhang X; Lu X; You L; Song Y; Luo Z; Zhang J; Nie J; Zheng W; Xu D; Wang Y; Dong Y; Yu S; Hong J; Shi J; Hao H; Luo F; Hua L; Wang P; Qian X; Yuan F; Wei L; Cui M; Zhang T; Liao Q; Dai M; Liu Z; Chen G; Meckel K; Adhikari S; Jia G; Bissonnette MB; Zhang X; Zhao Y; Zhang W; He C; Liu J
Cell Res; 2017 Oct; 27(10):1243-1257. PubMed ID: 28925386
[TBL] [Abstract][Full Text] [Related]
20. Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients.
Buttarelli M; Ciucci A; Palluzzi F; Raspaglio G; Marchetti C; Perrone E; Minucci A; Giacò L; Fagotti A; Scambia G; Gallo D
J Exp Clin Cancer Res; 2022 Feb; 41(1):50. PubMed ID: 35120576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
